Related Experiment Video

Updated: Dec 13, 2025

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.6K

A Review of Beta-Blocker Toxicity and Management Strategies

Kayla N Colunga, Justin P Reinert

    The Senior Care Pharmacist
    |July 29, 2020
    PubMed

    Insights

    Older adults are at higher risk for adverse effects from beta-blocker overdose. This review covers toxicity mechanisms and advanced treatments like high-dose insulin for managing beta-blocker poisoning in this population.

    Area of Science:

    • Cardiology
    • Geriatrics
    • Toxicology

    Background:

    • Beta-blockers are crucial for cardiovascular diseases common in older adults.
    • Older patients face increased risks due to polypharmacy, cognitive decline, and heightened sensitivity to beta-blocker effects.
    • Traditional overdose treatments may be less effective in this demographic.

    Purpose of the Study:

    • To review the mechanisms and effects of beta-blocker toxicity.
    • To summarize current and emerging management strategies for beta-blocker poisoning in older individuals.

    Main Methods:

    • Literature review of beta-blocker toxicity and management.
    • Analysis of poison center data regarding beta-blocker exposures in older adults.
    • Evaluation of evidence for novel therapies in beta-blocker overdose.

    Main Results:

    • In 2017, 21% of adult beta-blocker exposures involved patients aged 60+.
    • Older adults may exhibit increased sensitivity to hypotensive and bradycardic effects.
    • Novel therapies like high-dose insulin euglycemia and intravenous lipid emulsion show promise.

    Conclusions:

    • Beta-blocker toxicity poses a significant risk to the elderly population.
    • Management strategies must consider age-related factors and potential efficacy of newer treatments.
    • Further research into optimal overdose management for older adults is warranted.

    More Related Videos

    Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus08:28

    Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

    Published on: April 5, 2011

    18.1K
    A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique09:47

    A Rat Model of Ventricular Fibrillation and Resuscitation by Conventional Closed-chest Technique

    Published on: April 26, 2015

    16.2K

    Related Concept Videos

    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
    646
    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

    Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

    β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
    1.4K
    Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

    Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

    β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
    1.2K
    Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
    1.0K
    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

    Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

    Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
    1.2K
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    771